Holen Sie sich die Stockscreener-App
27.82
0.64%
-0.18
Vorhandelsmarkt:
27.76
-0.06
-0.22%
Schlusskurs vom Vortag:
$28.00
Offen:
$27.88
24-Stunden-Volumen:
385.02K
Relative Volume:
0.41
Marktkapitalisierung:
$870.49M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-69.47M
KGV:
-4.9703
EPS:
-5.5973
Netto-Cashflow:
$-73.92M
1W Leistung:
-9.44%
1M Leistung:
-0.82%
6M Leistung:
-4.69%
1J Leistung:
-22.36%
1-Tages-Spanne:
$27.65
$29.02
1-Wochen-Bereich:
$27.07
$31.58
52-Wochen-Spanne:
$16.54
$50.40
Lenz Therapeutics Inc Stock (LENZ) Company Profile
Firmenname
Lenz Therapeutics Inc
Sektor
Branche
Telefon
858-925-7000
Adresse
201 LOMAS SANTA FE DRIVE, SUITE 300, SOLANA BEACH
Vergleichen Sie LENZ mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
LENZ
Lenz Therapeutics Inc
|
27.82 | 876.12M | 0 | -69.47M | -73.92M | -5.5973 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.26 | 117.50B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.83 | 76.06B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.56 | 62.53B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
916.31 | 56.75B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
205.04 | 44.10B | 447.02M | -1.18B | -906.14M | -6.1812 |
Lenz Therapeutics Inc Stock (LENZ) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-14 | Fortgesetzt | Piper Sandler | Overweight |
| 2025-03-18 | Eingeleitet | TD Cowen | Buy |
| 2024-09-27 | Eingeleitet | Raymond James | Outperform |
| 2024-08-12 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-04-15 | Eingeleitet | Leerink Partners | Outperform |
| 2024-04-15 | Eingeleitet | William Blair | Outperform |
| 2024-04-10 | Eingeleitet | Citigroup | Buy |
| 2024-03-27 | Eingeleitet | Piper Sandler | Overweight |
| 2023-02-23 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2023-02-23 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2023-02-23 | Herabstufung | Cowen | Outperform → Market Perform |
| 2023-01-25 | Herabstufung | BTIG Research | Buy → Neutral |
| 2023-01-18 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-01-06 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2023-01-06 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2022-09-15 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-06-17 | Eingeleitet | BMO Capital Markets | Outperform |
| 2022-04-14 | Eingeleitet | BTIG Research | Buy |
| 2022-03-22 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2022-02-18 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2021-07-20 | Eingeleitet | Morgan Stanley | Overweight |
| 2021-07-20 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Lenz Therapeutics Inc Aktie (LENZ) Neueste Nachrichten
Will LENZ Therapeutics Inc. stock gain from strong economyJuly 2025 Highlights & Smart Swing Trading Alerts - Newser
Transcript : LENZ Therapeutics, Inc. Presents at Citi Annual Global Healthcare Conference 2025, Dec-04-2025 10 - marketscreener.com
Lenz Therapeutics: A Close Look (NASDAQ:LENZ) - Seeking Alpha
LENZ Therapeutics (NASDAQ:LENZ) Shares Down 6.1%Here's What Happened - MarketBeat
Skandinaviska Enskilda Banken AB publ Acquires New Stake in LENZ Therapeutics, Inc. $LENZ - MarketBeat
Lenz Therapeutics, Lotus Pharmaceutical Say New Drug Application for Presbyopia Treatment Submitted in South Korea - marketscreener.com
LENZ Therapeutics Announces MFDS Submission of New Drug Application for LNZ100 (VIZZ™) in South Korea for the Treatment of Presbyopia - The Manila Times
LENZ Therapeutics and Lotus Pharmaceutical Submit New Drug Application for VIZZ in South Korea to Treat Presbyopia - Quiver Quantitative
LENZ Therapeutics (Nasdaq: LENZ) logs 2nd ex-US VIZZ filing, up to $125 million milestones - Stock Titan
Piper Sandler 37th Annual Healthcare Conference - LENZ Therapeutics
LENZ Therapeutics to Present at Upcoming Investor Conferences - The Manila Times
LENZ Therapeutics (Nasdaq: LENZ) to webcast three December investor conferences - Stock Titan
Olsson, Lenz therapeutics CCO, sells $261k in stock By Investing.com - Investing.com Australia
Building trade automation scripts for LENZ Therapeutics Inc.July 2025 Closing Moves & Verified Momentum Stock Ideas - newser.com
Ranking LENZ Therapeutics Inc. among high performing stocks via toolsEarnings Recap Summary & Short-Term High Return Strategies - newser.com
How LENZ Therapeutics Inc. stock reacts to oil prices2025 Price Targets & High Return Stock Watch Alerts - newser.com
Olsson, Lenz therapeutics CCO, sells $261k in stock - Investing.com
LENZ Therapeutics CCO Shawn Olsson Sells 10,000 Shares - TradingView
Officer Olsson Sells 10,000 ($261K) Of LENZ Therapeutics Inc [LENZ] - TradingView
Is LENZ Therapeutics Inc. stock a buy in volatile marketsWeekly Profit Recap & Weekly Breakout Watchlists - newser.com
Signal strength of LENZ Therapeutics Inc. stock in tech scannersJuly 2025 Institutional & Weekly Stock Performance Updates - newser.com
How LENZ Therapeutics Inc. stock reacts to Fed rate cutsEarnings Risk Report & Technical Confirmation Alerts - newser.com
Is LENZ Therapeutics Inc. stock a dividend growth opportunityJuly 2025 Levels & Stepwise Entry and Exit Trade Signals - newser.com
Combining price and volume data for LENZ Therapeutics Inc.Trade Ideas & Stepwise Trade Signal Implementation - newser.com
Can LENZ Therapeutics Inc. stock maintain operating marginsRate Hike & Precise Swing Trade Entry Alerts - newser.com
Tools to assess LENZ Therapeutics Inc.’s risk profileWeekly Earnings Recap & Low Drawdown Trading Techniques - newser.com
Officer Olsson Files To Sell 40,000 Of LENZ Therapeutics Inc [LENZ] - TradingView
Chart overlay techniques for tracking LENZ Therapeutics Inc.Weekly Volume Report & Capital Protection Trading Alerts - newser.com
How interest rate cuts could boost LENZ Therapeutics Inc. stockWall Street Watch & Risk Adjusted Buy/Sell Alerts - newser.com
Will LENZ Therapeutics Inc. stock see PE expansionJuly 2025 Closing Moves & AI Powered Buy/Sell Recommendations - newser.com
Finanzdaten der Lenz Therapeutics Inc-Aktie (LENZ)
Umsatz
Nettogewinn
Free Cashflow
ENV
Lenz Therapeutics Inc-Aktie (LENZ) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Olsson Shawn | Chief Commercial Officer |
Nov 17 '25 |
Sale |
26.10 |
10,000 |
261,022 |
4,733 |
1.10%
1.10%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):